The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...

Know about the revolutionary therapies, personalised medicine and cancer treatments that are changing the game!

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.